Claude Nogard 0:03
My name is Claude Nogard, I'm CEO and co founder of Ergosuture. Next to me is reasonable DEVAR neurosurgeons, Lefty by birth and inventor of the water based drink system. Every teacher is before and foremost a surgeon company, we have raised $8.5 million to date 80% coming from surgeons. More importantly, over the past two years, we have been, you know, bombarded by surgeons from all around the world requesting access to our product for collaboration. We currently have 70 distributors requesting you know, commercialization, and some of them have already signed letter of intent to get the product. So who are we, we are experts in securing. And interestingly, suturing is very hard. Over the past 50 years, many products have been developed to improve strength. Unfortunately, none of them are as versatile and efficient as suturing. So our objective is very simple. We are reinventing the suturing process to make it easier and more efficient. In the process, we have you know, on boarded a tremendous amount of experts, people that have, you know, commercialized product for the past 30 years. And last year, we embodied map students and we frame who have been involved in the process of commercializing product. So what did we do last year, very simple. 20 minutes, we will show a demo test we beat we went outside of us, we presented a product more than 500 surgeons, we exhibited at more than five conferences alone or with partners. We also did our first data we share with you and what did we show them we introduced this the Wallabies featuring technology the first ever evolution altering process in more than a century. So what it is, what a basic training allow you to self right position and drive any door without ever talking your waist. Okay, thank you without ever breaking your wrist or using grasper. So let me show you what do you do with inexperienced using the device, I am a right hand surgeon using your left hand, go and grab it. I'm going to go forward just to show the motion going forward. Back is a little tip. And we go into this thing. I don't mean it's not I'm not even correcting for the angle. I'm just going to get the depth. It's going to pop out there release. And grab. Finish. Perfect smoothie just came in through beautiful. So you heard correctly. Dr. CEDS is a righty. And he tried the rest with the left hand. The reason why we show you that video is to share with you how easy is to use the device. Actually, we use that when we meet with search and have a very strong muscle memory to help him to extend that there is no need to work your waist. So what we have done, you know, after we invented the process, we made sure that our handle will be very consistent with surgeons are familiar ways. As you know, surgeons are very adverse to this change. So this basically handle here is very simple. It has two more comments want to actually the waters want to change direction of needle. So very simple to understand very intuitive. And so you might not believe that, but I will show you right now the data behind it. So that's why we're very excited. So we have never showed that to anybody. So this is the first data for you. So we want to test and want you to validate our technology across three parameters, time motion, and forces. Why forces because we use waters, and what it will do is to make sure that they will city to tissue. So the first test that you see here, we ask a surgeon to run five sutures. So very simple. In Orange is our product. So you will see that it's faster, but the biggest part is the four other forces applied to tissue never go over four Newton that means simply that the device provides due process that is consistent repeatable independent of the operator. So you met this one operator. So then you go to next study, we took 10 operators tense no surgeon with it at first in second year. You ask them to do the same thing again. And as you can see, once again did you have an old outperform the traditional driver of all parameters, motion forces, time easier, better faster. And so you might want to understand how the device works. So we should institute so look at this the needle will be separated. We position and driven by the surgeon without ever torquing his waist full control the bite, the ability to track the needle at will and basically you know catching the needle and putting up tissue will Without tweaking the waist to using the arc motion, which is perfect.
We have tried the device to work on all soft tissues, including the visual cuff. And you can see once again, it's repeatable, don't work on the wrist, and this needle will go smoothly to tissue without damaging the tissue. So what are the unmet needs that post post about with surgery, of course, better string time better learning curve, actually, the learning curve is five minutes. And this is not a joke. This is literally five minutes. Application robotic surgery for the learning curve that will give you more information about that. But also in terms of performance, because at least to date, robots are not faster suturing. And last but not least is application is endoluminal surgery, both handheld and robotic. So interestingly as to believe that animal surgery might be the most of the greatest application yet until you go into heart surgery, because they have no room to navigate and to manipulate tissue. The other challenge they have is deep in the room and you look you like forces to drive them to tissues. So our back ends about $5.5 million. And I will share with you the first three segments. So we'll enter into the basket pick movie do soft tissue for robotic and aluminum surgery. And eventually we'll go into heart. So this is the first device handheld device that has one handle that is usable, can be sterilized can be used for more than 200 surgeries. And you attach to it a single use is to lead to the fact that the device that we will not introduce me next year in the US and q4 next year in Europe. So initially for surgeries like general surgery, urology and gynecology will subsequently launched this device, it can be clinical, to make it smaller, so we can fit all hands, but also provide you know, a smooth transition, but also some articulation. And the next round is going to robotic. So something we have done on top of adding the waters is adding a CAM system. And what that means we can make out of a new driver grasper or Dissector. We can force open and close the jaws, we can vary the clamping force, which basically allow us especially in endosurgery, not to have to change instruments. And so we are right now looking for collaboration because we are not a robotic company. We focus on suture, that's what we do. And so let me show you basically the reason why robotic is prime for that. The study was released last year by Dr. Jaime. And what they did here is trying to extend the learning curve between novices intermediate surgeons and experts. And you can see that between 2001 2006 The or improved what you might want to pay attention in the forces for the surgeons, the novices also improved because of this visual haptic feedback learning. This is what you will have with a water based system. We actually consistently drive everything to do list. And the reason being is that the entire 42 applied are primarily based on a trigger pool, which is completely independent of the surgeon. And that's something that we are testing actually, we were preparing for the head to head so we can actually come back next year to show you that. And so what are the benefits of our product, we owned more than eight patents in the portfolio. We have a reasonable model we have needles developing to expand the reach. We have a cost access model that we're building, which is a match. And we can use that platform across the board from handheld laparoscopic to robotic. So we are currently closing under 15 million convertible note. But next year, we'll come to get an additional $10 million to get us to breakeven. So as you can see here, we will launch fairly quickly in the US and outside the US. So we will see not only in human health but also animal health. We all thought you'd have POS swag getting ready for that and moving forward to that. So during the evolution, the next generation of drivers Thank you
I am a Global Marketing Strategy Expert with 20 years experience in both US and international markets. I honed my skills and expertise at Merck & Co. and Novartis, working in various marketing functions, among which brand management, market development, and new product launches.
Over the past five years, I co-founded three companies: ErgoSurgical, an open source research boutique that partners with surgeons to design unique surgical solutions; Dynamic Suture DBA Ergosuture, a medical device company with an innovative suturing system for joining together skin and tissue layers of patients; ValSculp, a medical device company that specializes in the development of mitral and tricuspid solution applied via trans catheter and that uses sutures as primary anchors.
All these ventures are born from the understanding that technology has a key role to play in closing the global burden gap that exists in diseases treatable by surgery. They aim first and foremost to deliver comprehensive and accessible surgical solutions worldwide.
I am a Global Marketing Strategy Expert with 20 years experience in both US and international markets. I honed my skills and expertise at Merck & Co. and Novartis, working in various marketing functions, among which brand management, market development, and new product launches.
Over the past five years, I co-founded three companies: ErgoSurgical, an open source research boutique that partners with surgeons to design unique surgical solutions; Dynamic Suture DBA Ergosuture, a medical device company with an innovative suturing system for joining together skin and tissue layers of patients; ValSculp, a medical device company that specializes in the development of mitral and tricuspid solution applied via trans catheter and that uses sutures as primary anchors.
All these ventures are born from the understanding that technology has a key role to play in closing the global burden gap that exists in diseases treatable by surgery. They aim first and foremost to deliver comprehensive and accessible surgical solutions worldwide.
Claude Nogard 0:03
My name is Claude Nogard, I'm CEO and co founder of Ergosuture. Next to me is reasonable DEVAR neurosurgeons, Lefty by birth and inventor of the water based drink system. Every teacher is before and foremost a surgeon company, we have raised $8.5 million to date 80% coming from surgeons. More importantly, over the past two years, we have been, you know, bombarded by surgeons from all around the world requesting access to our product for collaboration. We currently have 70 distributors requesting you know, commercialization, and some of them have already signed letter of intent to get the product. So who are we, we are experts in securing. And interestingly, suturing is very hard. Over the past 50 years, many products have been developed to improve strength. Unfortunately, none of them are as versatile and efficient as suturing. So our objective is very simple. We are reinventing the suturing process to make it easier and more efficient. In the process, we have you know, on boarded a tremendous amount of experts, people that have, you know, commercialized product for the past 30 years. And last year, we embodied map students and we frame who have been involved in the process of commercializing product. So what did we do last year, very simple. 20 minutes, we will show a demo test we beat we went outside of us, we presented a product more than 500 surgeons, we exhibited at more than five conferences alone or with partners. We also did our first data we share with you and what did we show them we introduced this the Wallabies featuring technology the first ever evolution altering process in more than a century. So what it is, what a basic training allow you to self right position and drive any door without ever talking your waist. Okay, thank you without ever breaking your wrist or using grasper. So let me show you what do you do with inexperienced using the device, I am a right hand surgeon using your left hand, go and grab it. I'm going to go forward just to show the motion going forward. Back is a little tip. And we go into this thing. I don't mean it's not I'm not even correcting for the angle. I'm just going to get the depth. It's going to pop out there release. And grab. Finish. Perfect smoothie just came in through beautiful. So you heard correctly. Dr. CEDS is a righty. And he tried the rest with the left hand. The reason why we show you that video is to share with you how easy is to use the device. Actually, we use that when we meet with search and have a very strong muscle memory to help him to extend that there is no need to work your waist. So what we have done, you know, after we invented the process, we made sure that our handle will be very consistent with surgeons are familiar ways. As you know, surgeons are very adverse to this change. So this basically handle here is very simple. It has two more comments want to actually the waters want to change direction of needle. So very simple to understand very intuitive. And so you might not believe that, but I will show you right now the data behind it. So that's why we're very excited. So we have never showed that to anybody. So this is the first data for you. So we want to test and want you to validate our technology across three parameters, time motion, and forces. Why forces because we use waters, and what it will do is to make sure that they will city to tissue. So the first test that you see here, we ask a surgeon to run five sutures. So very simple. In Orange is our product. So you will see that it's faster, but the biggest part is the four other forces applied to tissue never go over four Newton that means simply that the device provides due process that is consistent repeatable independent of the operator. So you met this one operator. So then you go to next study, we took 10 operators tense no surgeon with it at first in second year. You ask them to do the same thing again. And as you can see, once again did you have an old outperform the traditional driver of all parameters, motion forces, time easier, better faster. And so you might want to understand how the device works. So we should institute so look at this the needle will be separated. We position and driven by the surgeon without ever torquing his waist full control the bite, the ability to track the needle at will and basically you know catching the needle and putting up tissue will Without tweaking the waist to using the arc motion, which is perfect.
We have tried the device to work on all soft tissues, including the visual cuff. And you can see once again, it's repeatable, don't work on the wrist, and this needle will go smoothly to tissue without damaging the tissue. So what are the unmet needs that post post about with surgery, of course, better string time better learning curve, actually, the learning curve is five minutes. And this is not a joke. This is literally five minutes. Application robotic surgery for the learning curve that will give you more information about that. But also in terms of performance, because at least to date, robots are not faster suturing. And last but not least is application is endoluminal surgery, both handheld and robotic. So interestingly as to believe that animal surgery might be the most of the greatest application yet until you go into heart surgery, because they have no room to navigate and to manipulate tissue. The other challenge they have is deep in the room and you look you like forces to drive them to tissues. So our back ends about $5.5 million. And I will share with you the first three segments. So we'll enter into the basket pick movie do soft tissue for robotic and aluminum surgery. And eventually we'll go into heart. So this is the first device handheld device that has one handle that is usable, can be sterilized can be used for more than 200 surgeries. And you attach to it a single use is to lead to the fact that the device that we will not introduce me next year in the US and q4 next year in Europe. So initially for surgeries like general surgery, urology and gynecology will subsequently launched this device, it can be clinical, to make it smaller, so we can fit all hands, but also provide you know, a smooth transition, but also some articulation. And the next round is going to robotic. So something we have done on top of adding the waters is adding a CAM system. And what that means we can make out of a new driver grasper or Dissector. We can force open and close the jaws, we can vary the clamping force, which basically allow us especially in endosurgery, not to have to change instruments. And so we are right now looking for collaboration because we are not a robotic company. We focus on suture, that's what we do. And so let me show you basically the reason why robotic is prime for that. The study was released last year by Dr. Jaime. And what they did here is trying to extend the learning curve between novices intermediate surgeons and experts. And you can see that between 2001 2006 The or improved what you might want to pay attention in the forces for the surgeons, the novices also improved because of this visual haptic feedback learning. This is what you will have with a water based system. We actually consistently drive everything to do list. And the reason being is that the entire 42 applied are primarily based on a trigger pool, which is completely independent of the surgeon. And that's something that we are testing actually, we were preparing for the head to head so we can actually come back next year to show you that. And so what are the benefits of our product, we owned more than eight patents in the portfolio. We have a reasonable model we have needles developing to expand the reach. We have a cost access model that we're building, which is a match. And we can use that platform across the board from handheld laparoscopic to robotic. So we are currently closing under 15 million convertible note. But next year, we'll come to get an additional $10 million to get us to breakeven. So as you can see here, we will launch fairly quickly in the US and outside the US. So we will see not only in human health but also animal health. We all thought you'd have POS swag getting ready for that and moving forward to that. So during the evolution, the next generation of drivers Thank you
Market Intelligence
Schedule an exploratory call
Request Info17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy